- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03813498
Hepatitis C Patient Management and Family Health Education
Health Education Based on We Media to Promote Patient Adherence to HCV Treatment: A Nationwide Online Randomized Controlled Trial
INTRODUCTION: Hepatitis C virus (HCV) is recognized as the leading cause of chronic liver disease worldwide. However, the screening rate and treatment rate of HCV-infected patients in China is low, which increases the burden of patients and the infection risk of their family members. WeChat, an instant messaging software, is used in a very high proportion in China. Health promotion based on WeChat public platform is a very convenient and effective way of health education. Therefore, this study plans to apply WeChat to conduct health intervention for HCV-infected patients. The objective is to explore the effect of We-media-based health promotion method on the detection rate and treatment rate of HCV-infected and their family members.
METHOD: Recruitment will be conduct in 10 hospitals in Jilin, Beijing, Henan and Anhui provinces. The subjects should be patients new diagnosed with hepatitis C at the hospital and aged 18 to 69. After signing the consent form, eligible participants were selected through the inclusion and exclusion criteria. 1000 participants will be recruited for the trial. After completing an baseline reseach by a online questionnaire, patients will be randomly assigned to receive a targeted short article on HCV weekly or a general health article with no mention of HCV. The intervention will last three months and a follow-up will be conduct at three month after the last intervention.
OUTCOMES: The primary outcome is antiviral therapy. The secondary outcomes are cognition and attitude towards hepatitis C, factors influencing antiviral therapy, time to first treatment and the compliance of treatment.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Anticipado)
Fase
- No aplica
Contactos y Ubicaciones
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Permanent residents in the province
- Ages 18-69 (inclusive)
- Both blood anti-HCV test and HCV-RNA test is positive
- Familiar with the use of mobile phones and WeChat
- Informed consent and voluntary participation in the study
Exclusion Criteria:
- Temporary staff who come to the city to work, travel or visit relatives, or those who will be living in other cities for a long time
- Suffering from other serious diseases
- Patients with mental disorder or memory disorder
- Pregnant women or those who have a plan to prepare for pregnancy within one year
- Refuse to participate in the investigation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: grupo de intervención
|
The intervention group receive a targeted short article on HCV from WeChat weekly.
|
|
Otro: grupo de control
|
The control group receive a general health article with no mention of HCV from WeChat weekly.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of antiviral therapy
Periodo de tiempo: 6 months after the first intervention
|
The rate of antiviral therapy is equal to the number of subjects received antiviral therapy divide by the number of all subjects.
|
6 months after the first intervention
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to first treatment
Periodo de tiempo: 6 months after the first intervention
|
This is the interval time between the first intervention and first treatment.
We want to know from this outcome how long it takes the subject to receive the health intervention before starting treatment.
Thus, we can analyze the relationship between intervention time and treatment behavior.
|
6 months after the first intervention
|
|
Cognition and attitude towards hepatitis C
Periodo de tiempo: 6 months after the first intervention
|
Investigators designed a standardized questionnaire that asked questions about subjects' knowledge and attitudes toward hepatitis C. The scores of the questionnaire were used to evaluate the cognition and attitude of the subjects.
|
6 months after the first intervention
|
|
Factors influencing antiviral therapy
Periodo de tiempo: 6 months after the first intervention
|
The investigators designed a ranking question of factors that interfered with the subjects' treatment in the questionnaire.
These factors include: (1) My condition is not serious; (2) I am worried about the side effects of treatment; (3) I am afraid of being discriminated against because someone know I have the disease; (4) I have financial difficulties (or the treatment costs are too high); (5) The process of visiting a doctor is complicated.
Subjects can also fill in their own ideas in the blank if they have other factors not mentioned in this questionnaire.
Investigators will analyze the extent to which each factor affects a patient's treatment.
|
6 months after the first intervention
|
|
The rate of giving up treatment halfway
Periodo de tiempo: 6 months after the first intervention
|
This rate is used to assess compliance with treatment.
This rate is equal to the number of subjects who give up treatment halfway divided by the number of subjects who get treatment.
|
6 months after the first intervention
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Fuqiang Cui, PhD, Peking University
- Investigador principal: Tianshuo Zhao, Study Director
- Investigador principal: Yingsheng Shen, China Liver Health
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Anticipado)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades del HIGADO
- Infecciones por Flaviviridae
- Hepatitis, Viral, Humana
- Infecciones por enterovirus
- Infecciones por Picornaviridae
- Hepatitis
- Hepatitis A
- Hepatitis C
Otros números de identificación del estudio
- IN-CN-987-5377
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .